Prevalence of antibodies against seasonal influenza A and B viruses among older adults in rural Thailand: A cross-sectional study

Nungruthai Suntronwong, Preeyaporn Vichaiwattana, Lakkhana Wongsrisang, Sirapa Klinfueng, Sumeth Korkong, Thanunrat Thongmee, Nasamon Wanlapakorn, Yong Poovorawan

Faculty of Medicine, Department of Pediatrics, Center of Excellence in Clinical Virology, Chulalongkorn University, Bangkok, Thailand

*yong.p@chula.ac.th

Abstract

Assessing the seroprevalence of the high-risk individuals against the influenza virus is essential to evaluate the progress of vaccine implementation programs and establish influenza virus interventions. Herein, we identified the pre-existing cross-protection of the circulating seasonal influenza viruses among the older-aged population. A cross-sectional study was performed based on the 176 residual sera samples collected from older adults aged 60 to 95 years without a history of vaccination in rural Thailand in 2015. Sera antibody titers against influenza A and B viruses circulating between 2016 and 2019 were determined by hemagglutination inhibition assay. These findings indicated the low titers of pre-existing antibodies to circulating influenza subtypes and showed age-independent antibody titers among the old adults. Moderate seropositive rates (HAI ≥ 1:40) were observed in influenza A viruses (65.9% A(H3N2), 50.0% for A(H1N1) pdm09), and found comparatively lower rates in influenza B viruses (14% B/Yam2, 21% B/Yam3 and 25% B/Vic). Only 5% of individuals possessed broadly protective antibodies against both seasonal influenza A and B virus in this region. Our findings highlighted the low pre-existing antibodies to circulating influenza strains in the following season observed in older adults. The serological study will help inform policy-makers for health care planning and guide control measures concerning vaccination programs.

Introduction

The influenza virus is a significant pathogen that causes respiratory tract infections resulting in substantial morbidity and mortality during the annual influenza epidemic. A previous report indicated that influenza-associated deaths were estimated globally to be 290,000 to 650,000 individuals each year [1]. Influenza vaccination is a primary tool to effectively prevent influenza infection and reduce severe influenza-related sequelae [2]. The Advisory Committee on Immunization Practices (ACIP) recommends influenza vaccination of individuals at risk.
for severe complications, including pregnant women, young children (6–59 months), older adults, individuals with chronic medical conditions, and health care personnel [3].

Among the high-risk groups, the highest influenza-related mortality rate typically occurs among individuals older than 65 years of age (2.9 to 44 per 100,000 individuals for persons aged 65–74 years and 17.9 to 223.5 per 100,000 individuals for people aged over 75 years) [4]. Increases in influenza-associated hospitalization and death in this age group occur most frequently in individuals with co-morbidities and immunosuppression [5–7]. With advanced age, a meta-analysis indicated that vaccine effectiveness (VE) against influenza-like illness (ILI) and laboratory-confirmed influenza were estimated as approximately 39% and 49%, respectively, in older adults [8]. This result is most likely due to immunosenescence, which is a major contributing factor to increasing infection susceptibility and directly leads to a decline in the immune response, both humoral and cell-mediated immunity [9]. Although older adults could not maintain the seroprotective titers to the vaccine strain and most of these levels likely wane prior to the next season; individuals receiving the influenza vaccine might have a lower risk of influenza infection (from 6% to 2.4%) than an individual who has not been vaccinated [10]. Therefore, monitoring the immunity status of influenza viruses should be considered in older adults.

The older-aged population (≥ 60 years of age) has increased by 1.2% in Thailand, from 10.7 million in 2015 to 13 million in 2020 [11]. Vaccination with the annual influenza vaccine in individuals aged more than 65 has been recommended since 2008 to reduce the influenza burden [12,13]. Several studies have reported the seroprevalence rate among high-risk groups such as young children, health care workers, individuals with chronic medical conditions, and pregnant women [14–16]. Data of seroprevalence is valuable in pandemic scenarios and helps determine pre-existing immunity and reflect vaccine coverage. However, the seroprevalence data of the older-aged population are lacking. Thus, we aim to assess existing antibodies against seasonal influenza A/H1N1pdm09, A/H3N2, and B viruses to determine the seropositive rates in individuals aged older than 60 years.

Materials and methods

Ethical approval

The Institutional Review Board approved the study protocol, which was conducted according to the principles of the Declaration of Helsinki and the Good Clinical Practice Guidelines (ICH-GCP) of the Faculty of Medicine of Chulalongkorn University (IRB No. 127/61). The IRB waived the need for consent as the study on anonymized residual samples.

Serum samples

In our study, 176 residual sera (~200 μL) from a cross-sectional descriptive study performed in the rural northeastern region of Thailand (Chum Phae, Khon Kaen province) from October to November 2015 were obtained [17]. Serum samples were collected from older adults aged ≥60 years. Serological testing against influenza A/H1N1pdm09, A/H3N2, and influenza B viruses were performed for individual serum samples. Data regarding the date of vaccination and the date of the previous infection were not recorded.

Representative influenza viruses

To identify the presence of anti-influenza antibodies, we selected the representative influenza A/H1N1pdm09, A/H3N2, B/Victoria, and B/Yamagata viruses that circulated during the 2017–2019 influenza season as the test viruses. The nasopharyngeal swabs tested positive for
influenza A/H1N1pdm09, and A/H3N2 were propagated in 80% confluent Madin-Darby canine kidney (MDCK) cells [18] and incubated at 37˚C for 3–5 days, while the influenza B virus was grown and incubated at 33˚C for three days. The supernatants were collected and inoculated in embryonated chicken eggs that incubated at 37˚C for 48 h. Eggs were then cooled to 4˚C overnight, and the allantoic fluids were harvested and cleared by centrifugation. All viruses were subjected to conventional PCR and Sanger sequencing. The primer sets for both influenza A and B viruses have been described elsewhere [19,20].

The nucleotide sequences of the propagated viruses were assembled using Seq-Man Pro (DNASTAR, Madison, WI, USA) compared to the nucleotide sequences of the original samples using MUSCLE. Phylogenetic tree for each influenza type and subtype was constructed using the nucleotide sequences obtained from this study and southern hemisphere vaccines in 2015 available from the Global Initiative for Sharing All Influenza Data (GISAID) (http://platform.gisaid.org) database (S1 Fig). Trees were generated using the maximum-likelihood method and implemented in MEGAX [21]. The tested viruses were A/Thailand/CU-CN364/2017 (clade 6B.1) for A/H1N1pdm09 (accession No. MW600330) and A/Thailand/CU-B36461/2018 (clade 3C.3a) for A/H3N2 (accession No. MW600331). The B/Thailand/CU-B31196/2019 (accession No. MT803438), B/Massachusetts/02/2012_E1 (MW600489), and B/Thailand/CU-B26097/2018 (accession No. MT803450) were chosen as representative for the B/Victoria clade 1A, B/Yamagata clade 2, and B/Yamagata clade 3, respectively.

Hemagglutinin inhibition assay

All sera were stored at -20˚C and brought to room temperature before testing. Serum samples were quantitatively assessed to determine the antibody titer in duplicate using the hemagglutinin inhibition (HAI) assay, as described previously [22]. Individual serum samples were pretreated with the receptor-destroying enzyme (RDE; Denka Seiken, Tokyo, Japan) at a dilution of 1:4 and then incubated at 37˚C overnight to remove nonspecific inhibitors of hemagglutinin. Serum samples were further incubated at 56˚C to inactivate the process, which was followed by adding phosphate-buffered saline to achieve a 1:10 dilution. RDE-treated sera were tested for nonspecific HA activity using 0.5% suspension turkey red blood cells. If agglutinin appeared, adsorption of sera with turkey red blood cells could be performed by incubating the packed RBCs, and RDE treated serum at 4˚C for 1 h. Two-fold serial dilution (25 μL) of RDE-treated sera were prepared in a 96-well V-bottom plate starting at a 1:10 dilution and subsequently incubated with 25 μL of the tested virus (4 HA units per 25 μL) at room temperature for 30 min. The hemagglutination titer was read after adding a 0.5% suspension of turkey red blood cells and was incubated at 4˚C for 1 h. The highest reciprocal of the serum dilution that completely inhibited hemagglutination was recorded as the endpoint titer. A HAI titer more than or equal to 40 was considered protective against the tested virus [23,24]. We compared the antibody level. A HAI titer less than 10 was assigned a value of 5 to calculate the geometric mean titer (GMT) as in previous studies [25,26].

Statistical analysis

Seropositive rate was calculated using the number of individuals who were seropositive (considering only HAI titer ≥ 1:40) divided by the total number of subjects. The estimated data points for each influenza type or subtype were reported as a number, percentage, and 95% confidence intervals (CI). The differences between categorical variables (gender, age, and chronic disease) were evaluated by the chi-square test. The Dunn procedure was used as a posttest for pairwise comparisons of antibody titers among influenza types or subtypes following significant Friedman tests. The Spearman rank correlation between age and antibody titers for...
influenza virus was computed using R v3.6.0 (R Foundation for Statistical Computing, Vienna, Austria; https://www.r-project.org). All statistical analyses were performed using SPSS version 23 (IBM Corp., Armonk, NY, USA) and GraphPad Prism version 8.0.0 (GraphPad, San Diego, CA, USA; https://www.graphpad.com). The $p$ value $\leq 0.05$ was considered statistically significant.

Results

Patient characteristics

This study included 176 subjects, 21.6% (38/176) men and 78.4% (138/176) women. Their ages ranged from 60 to 95 years with a median of 69 (IQR:10.8) years. Approximately 48.86% (86/176) of this population presented at least one type of underlying disease, including diabetes mellitus with and without hypertension, were 18.6% (16/86) and 38.38% (33/86), respectively. Of 86, 40.7% of participants only presented hypertension and 1.16% combined hypertension and coronary heart disease. Moreover, 1.16% of participants showed diabetes mellitus combined with hypertension and coronary heart disease (S1 Table). Serum samples tested with the circulating influenza strains and the HAI-specific antibody titers are shown in S2 Table.

Antibody titers against influenza A and B viruses

Among the 176 tested samples, the geometric mean titers among influenza A subtypes in the elderly indicated that the highest antibody level was 47.8 (95% CI: 40.6–56.2), which was detected against influenza A/H3N2 (Table 1). While the HAI-specific antibodies of influenza A/H1N1pdm09 were 23.1 (95% CI: 19.0–28.2), which was significantly lower than that of influenza A/H3N2 ($p<0.001$) (Fig 1). Among influenza B viruses, the geometric mean titer of influenza B/Victoria (19.6, 95% CI: 17.4–22.1) and B/Yamagata 3 (17.9, 95% CI: 15.9–20.1) were significantly higher than that of the B/Yamagata 2 lineage (10.7, 95% CI: 9.4–12.1) ($p<0.001$). Furthermore, the HAI-specific antibody titers to both influenza A subtypes were slightly higher than those of the influenza B virus in this study population.

We analyzed associations between age and geometric mean titers (GMT). The results showed no significant correlation between age and the antibody titers to substantial influenza strains in the next season (Fig 2). It suggested that the antibody titers were age-independent among the older adults.

| Influenza virus | $^a$HAI titer $\geq$ 1:40 | $^b$GMT |
|----------------|----------------------------|---------|
|                | Number/Total | %  | Mean  | Mean | 95%CI |
| Influenza A virus |               |   |       |      |       |
| A/H1N1pdm09     | 88/176        | 50.0 | 23.14 | 18.99 | 28.19 |
| A/H3N2          | 116/176       | 65.91 | 47.76 | 40.56 | 56.23 |
| Influenza B virus |               |   |       |      |       |
| B/Victoria      | 44/176        | 25.00 | 19.61 | 17.42 | 22.08 |
| B/Yamagata 2    | 25/176        | 14.20 | 10.69 | 9.42 | 12.13 |
| B/Yamagata 3    | 37/176        | 21.02 | 17.91 | 15.94 | 20.13 |

$^a$ HAI, hemagglutination inhibition; 
$^b$ GMT, Geometric means titers.

https://doi.org/10.1371/journal.pone.0256475.t001
Seroprevalence of influenza A and B virus among older adults

Overall, a higher seroprevalence against influenza A virus than influenza B virus was observed (Table 1). The highest seropositive rates were found in individuals who were possess seropositivity for influenza A/H3N2 antibodies, which accounted for 65.91% (116/176). The seropositive rates for influenza A/H1N1pdm09 were subsequently estimated to be 50% (88/176). Although the seroprevalence of either influenza A/H1N1pdm09 or A/H3N2 antibodies were estimated to be approximately half that of the study populations, the individuals who tested seropositive for both influenza A subtypes comprised 29.5% (52/176). Unlike the influenza A virus, the proportion of individuals who tested positive for influenza B antibodies was low. The seropositive rates did not significantly differ between B/Victoria (25%) and B/Yamagata 3 (21%). Approximately 12% (21/176) of the elderly possessed antibodies against B/Victoria and B/Yamagata lineages.

In the analysis stratified by age groups, most individuals presented higher seropositive rates of influenza A virus than influenza B virus (Fig 3). Although there was no significant difference in seroprevalence rates among the age groups for influenza A virus, individuals were more
likely to possess more antibodies against influenza A/H3N2 than influenza A/H1N1pdm09 (S3 Table). The lowest seroprevalence was noticed for the B/Yamagata lineages, which appeared to decrease dramatically in individuals older than 80 years of age (Y2: p = 0.068, Y3: p = 0.002). However, there were no statistically significant differences in seropositive rates based on gender or chronic diseases (S4 Table).
Low seropositive rates for all influenza types or subtypes

To identify the proportion of individuals who presented broad protective antibodies, we determined the number of individuals who were seropositive against at least one influenza type or subtype. Overall, 89% (156/176) of the elderly individuals in our study possessed antibodies against at least one influenza type or subtype, while 11% (20/176) of individuals was seronegative (Fig 4). The heterologous immunity of different influenza B lineage was relatively lower (11.93%) than different influenza A subtypes (30.68%). Although most individuals (42%) were seropositive to one influenza type or subtype, approximately 5% of this population possessed
the antibodies to four influenza types or subtypes which indicated a small proportion of individuals provided broadly protective antibodies to all seasonal influenza viruses.

Discussion

Herein, we identified the prevalence of pre-existing antibodies against the seasonal influenza viruses among the older aged population in a rural area of Thailand. Our study found that most antibodies against influenza A viruses were moderate in aging adults, while the antibodies against influenza B viruses were comparatively lower. There was an age-independent antibody titer found in individuals older than 60 years of age. Further, a small proportion of the elderly possessed broadly seroprotective antibodies to all seasonal influenza viruses in this study.

A moderate protective level of antibodies to the influenza A virus might occur because of the seasonal epidemic of the influenza A virus [27]. A newly antigenic drift virus was introduced, resulting in the typical influenza epidemic. Exposure to the drifted influenza virus was able to increase or maintain pre-existing immunity [28]. Moreover, time since infection may be related to different titers of HAI-specific antibodies. Since influenza A(H1N1)pdm09 emerged in 2009, the incidence was peak dramatically from 2010 until mid-2011 [29]. Although influenza A(H1N1)pdm09 remains circulated since then, the predominant subtype was influenza A (H3N2) [27]. Typically, the level of antibody detection decrease with time since exposure to the historical strains [30]; it was probably related to the antibody titers to A (H1N1) pdm09 comparatively lower than A(H3N2) virus. Furthermore, the highest titer of HAI-specific antibodies to A/H3N2 was consistent with the predominant subtype of the influenza A virus, A/H3N2, in the 2015 influenza season in Thailand (June to August) [31].

A low protective level against influenza B virus might be related to the annually sporadic circulating activity compatible with influenza A virus [27]. According to influenza surveillance indicated that the B/Victoria-lineage was predominant between 2010–2012, while B/Yamagata lineage (clade 2) was significantly distributed in 2013 until the first half of 2014 and replaced by B/Yamagata (clade 3) since then [20,32]. It was consistent with our results indicated the antibody titers of B/Yamagata clade 3 comparatively higher than B/Yamagata clade 2. Although B/Victoria was less predominant in 2013, the antibody to B/Victoria remains higher presented in older adults than B/Yamagata clade 3. In addition, the evolution rate of influenza B hemagglutinin, the main antigenic determinant protein, is substantially lower than for the influenza A virus [33]. The higher seropositive rates to influenza B/Victoria than to the influenza B/Yamagata are consistent with a previous study from Spain [34]. However, the heterologous of different influenza B lineages was observed, which may relate to the lineage shift evidence between 2014–2016 [32]. Furthermore, the fewer individuals who possessed antibodies to those viruses might be related to the inferior persistence of antibodies against the influenza B virus compared to the influenza A virus [35].

The seroprotection was defined as HAI titer ≥ 1:40 that typically corresponds to a 50% protection against influenza infection in the elderly when the virus matched the circulating strains; in contrast, a higher titer (203–437) was required to achieve the mismatched viruses [36]. Our study found that most individuals did not show high titers against influenza A and B viruses, which may result from individuals who have never been vaccinated or from individuals whose immunity has waned [9]. The previous report found that the pre-existing immunity to the influenza virus affects the rate of increasing seroconversion in both younger and older people and can raise the breadth of immune responses following influenza vaccination [30,37]. However, there is evidence that HI titers in older adults do not reliably persist year-round and more likely to decline prior to the next season [37,38].
Vaccination of the elderly is a practical approach to reduce the likelihood of experiencing disease and death caused by influenza virus infection [8]. According to influenza vaccination guidelines [39], the authorities recommend that vaccine coverage for individuals older than 65 against seasonal influenza should exceed 75%. An evaluation of influenza vaccination following its introduction in Thailand suggests that the number of vaccines purchased increased by 25% [40]. Although a previous report estimated that the vaccine coverage among the elderly increased from 12% (2010) to 20% (2016), a smaller proportion of individuals who showed broad protection to all influenza types or subtypes remained small in this study [41]. It reflects a lower vaccine uptake in the elderly and suggests the need for proactive public health intervention and preventive measures.

There are some limitations to this study. There is a lack of information regarding the previous history of influenza infections and the date of individual vaccinations. It was hard to interpret the source of influenza immunity, whether it be due to immunization or natural exposure. The results from the hemagglutination inhibition assay do not indicate the levels of all protective antibody including anti-hemagglutinin stalk antibodies and the anti-neuraminidase antibodies. Nevertheless, our study did not perform the assay that measured the functional antibodies such as neutralization assays or ELISA. Tests for cellular immunity were not performed in this study, although these may also be associated with protection [42]. Furthermore, the tested viruses used in this study lacked A/H3N2 clade 3C.2a, which has been the predominant circulating strain since 2016. Thus, we may have underestimated the cross-reactivity against A/H3N2.

As Thailand continues to increase influenza vaccination among high-risk groups, the continued monitoring of the influenza immunity profile among those populations should be performed [12,13]. Our findings indicated that fewer individuals possessed antibodies against seasonal influenza virus among the older aged population and highlight the need to improve the vaccine policies in rural areas of Thailand. A serological study of high-risk individuals will be necessary to assess vaccination progress and reflect the need for further public health intervention to combat influenza. This study emphasizes the need to raise concerns among vaccine policy-makers for high-risk populations.

Supporting information

S1 Fig. Schematic showed the phylogenetic trees of representative tested virus compared with their vaccine strain. Phylogenetic analyses of the nucleotide sequences of HA coding region of (A) influenza A/H1N1pdm09, (B) influenza A/H3N2, (C) B/Victoria, (D) B/Yamagata were compared with their vaccine strains and reference strains of known clades which available from the database. Color dot indicates the tested virus that used in this study. (TIF)

S1 Table. Demographic of participants. (DOCX)

S2 Table. Hemagglutination inhibition titers (HAI titers) against the individual seasonal influenza type or subtype among the older adults in rural, Thailand. (DOCX)

S3 Table. Comparison the seropositive rates (HAI titers ≥ 1:40) against seasonal influenza viruses among different aged groups. (DOCX)
S4 Table. Comparison the seropositive rates (HAI titers ≥ 1:40) against seasonal influenza viruses by gender, age groups and individuals with or without chronic disease.

(DOCX)

Acknowledgments
The authors would like to thank Dr. Wanpen Chaicumpa at Center of Research Excellence on Therapeutic Proteins and Antibody Engineering, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, for providing the Madin-Darby Canine Kidney (MDCK) cell line.

Author Contributions
Conceptualization: Nungruthai Suntronwong.
Data curation: Nungruthai Suntronwong, Preeyaporn Vichaiwattana.
Formal analysis: Nungruthai Suntronwong, Yong Poovorawan.
Funding acquisition: Nungruthai Suntronwong, Yong Poovorawan.
Investigation: Nungruthai Suntronwong, Lakkhana Wongsrisang, Sirapa Klinfueng, Sumeth Korkong.
Methodology: Nungruthai Suntronwong, Preeyaporn Vichaiwattana, Thanunrat Thongmee.
Project administration: Yong Poovorawan.
Resources: Yong Poovorawan.
Software: Nungruthai Suntronwong.
Supervision: Yong Poovorawan.
Validation: Yong Poovorawan.
Visualization: Nungruthai Suntronwong, Nasamon Wanlapakorn, Yong Poovorawan.
Writing – original draft: Nungruthai Suntronwong.
Writing – review & editing: Nungruthai Suntronwong, Nasamon Wanlapakorn, Yong Poovorawan.

References
1. WHO. Up to 650 000 people die of respiratory diseases linked to seasonal flu each year. https://www.who.int/news-room/detail/14-12-2017-up-to-650-000-people-die-of-respiratory-diseases-linked-to-seasonal-flu-each-year Cited 25 September, 2020. 2017.
2. CDC. Vaccine Benefits [Internet]. https://www.cdc.gov/flu/prevent/vaccine-benefits.htm. Cited 25 September, 2020.
3. MMWR. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2020–21 Influenza Season. MMWR Recomm Rep. 2020; 69(RR-8):1–24. https://doi.org/10.15585/mmwr.rr6908a1 PMID: 32820746.
4. Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018; 391(10127):1285–300. https://doi.org/10.1016/S0140-6736(17)33293-2 PMID: 29248255.
5. Bitterman R, Elaikim-Raz N, Vinograd N, Trestioreanu AZ, Leibovici L, Paul M. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev. 2018;(2). https://doi.org/10.1002/14651858.CD008983.pub3 PMID: 29388679.
25. Stephens I, Heath A, Major D, Newman RW, Hoschler K, Junzi W, et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis. 2009; 15(8):1250. https://doi.org/10.3201/eid1508.081754 PMID: 19751587.

24. WHO. WHO Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. World Health Organization. 2011;252.

23. Cox R. Correlates of protection to influenza virus, where do we go from here? Hum Vaccin Immunother. 2013; (9):2;405–8. https://doi.org/10.4161/hv.22908 PMID: 23291930.

22. WHO. WHO Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. World Health Organization. 2011;252.

21. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol. 2018; 35(6):1547. http://doi.org/10.1093/molbev/msy086 PMID: 29722887.

20. Tewawong N, Suwannakarn K, Prachayangprecha S, Korkong S, Klinfueng S, Vongpunsawad S, et al. Molecular epidemiology and phylogenetic analyses of influenza B virus in Thailand during 2010 to 2014. PLoS One. 2015; 10(1):e0116302. http://doi.org/10.1371/journal.pone.0116302 PMID: 25602617.

19. Tewawong N, Prachayangprecha S, Vichiwattana P, Korkong S, Klinfueng S, Vongpunsawad S, et al. Assessing antigenic drift of seasonal influenza A (H3N2) and A (H1N1) pdm09 viruses. PLoS one. 2015; 10(10):e0139958. http://doi.org/10.1371/journal.pone.0139958 PMID: 26440103.

18. Thueng-in K, Maneewatch S, Ditsungnoen D, Kittikraisak W, Phadungkiatwatana P, Ditsungnoen D, Kaoiean S, Macareo L, Rungrojcharoenkit K, et al. Comparison of influenza antibody titers among women who were vaccinated in the 2nd and the 3rd trimesters of pregnancy. Vaccine. 2021; 39(1):18–25. https://doi.org/10.1016/j.vaccine.2020.11.032 PMID: 33246364.

17. Prachayangprecha S, Makkoch J, Payungporn S, Chieochansin T, Vuthitanachot C, Vuthitanachot V, et al. Serological analysis of human pandemic influenza (H1N1) in Thailand. J Health Popul Nutr. 2010; 28(6):537. https://doi.org/10.3329/jhpn.v28i6.6601 PMID: 21261198.

16. Chinchai T, Posuwan N, Vuthitanachot V, Thamaporplilas P, Ditsungnoen D, Kaoiean S, Macareo L, Rungrojcharoenkit K, et al. Immunization policy development in Thailand: the role of the Advisory Committee on Immunization Practice. Vaccine. 2010; 28:A104–A9. https://doi.org/10.1016/j.vaccine.2010.02.043 PMID: 20412989.

15. Kittikraisak W, Phadungkiatwatana P, Ditsungnoen D, Kaoiean S, Macareo L, Rungrojcharoenkit K, et al. Comparison of influenza antibody titers among women who were vaccinated in the 2nd and the 3rd trimesters of pregnancy. Vaccine. 2021; 39(1):18–25. https://doi.org/10.1016/j.vaccine.2020.11.032 PMID: 33246364.

14. Chokephaibulkit K, Assanasen S, Apisamthanarak A, Rongrungruang Y, Kachintorn K, Tuntiwattanapibul Y, et al. Seroprevalence of 2009 H1N1 virus infection and self-reported infection control practices among healthcare professionals following the first outbreak in Bangkok, Thailand. Influenza Other Respir Viruses. 2013; 7(3):359–63. https://doi.org/10.1111/irv.12016 PMID: 23043536.

13. Muangchanan C, Thanompongplia P, Karakwinpong O. Immunization policy development in Thailand: the role of the Advisory Committee on Immunization Practice. Vaccine. 2010; 28:A104–A9. https://doi.org/10.1016/j.vaccine.2010.02.043 PMID: 20412989.

12. Surichan S, Wirachwong P, Supachaturachart C, Vamvoravudh P, et al. Development of influenza vaccine production capacity by the Government Pharmaceutical Organization of Thailand: addressing the threat of an influenza pandemic. Vaccine. 2011; 29:A29–A33. https://doi.org/10.1016/j.vaccine.2011.04.120 PMID: 21684425.

11. HelpAge International network. The situation of Thailand’s older population [Online]. https://www.ageingasia.org/ageing-population-thailand. Cited 8 February 2021.

10. Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2018;(2). https://doi.org/10.1002/14651858.CD001269.pub6 PMID: 29388196.

9. Haq K, McElhany JE. Immunosenescence: influenza vaccination and the elderly. Curr Opin Immunol. 2014; 29:38–42. https://doi.org/10.1016/j.coi.2014.03.008 PMID: 24769424.

8. Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD. Cochrane review of immunization policy development in Thailand: support for policies to vaccinate elderly people against influenza. Vaccine. 2013; 31 (50):6030–3. https://doi.org/10.1016/j.vaccine.2013.09.063 PMID: 24095882.

7. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004; 292(11):1333–40. https://doi.org/10.1001/jama.292.11.1333 PMID: 15367555.

6. Schanzer DL, Langley JM, Tam TW. Co-morbidities associated with influenza-attributed mortality, 1994–2000, Canada. Vaccine. 2008; 26(36):4697–703. https://doi.org/10.1016/j.vaccine.2008.06.087 PMID: 18620016.

5. Panich L, Thipayarangkul K, Suwannakarn K, Prachayangprecha S, Makkoch J, Payungporn S, Chieochansin T, Vuthitanachot C, Vuthitanachot V, et al. Serological analysis of human pandemic influenza (H1N1) in Thailand. J Health Popul Nutr. 2010; 28(41):6765–77. http://doi.org/10.1016/j.vaccine.2010.07.065 PMID: 20688037.

4. Vongpunsawad S, Prachayangprecha S, Vichiwattana P, Pitsungnoen D, Kaoiean S, Macareo L, Rungrojcharoenkit K, et al. Comparaison of influenza antibody titers among women who were vaccinated in the 2nd and the 3rd trimesters of pregnancy. Vaccine. 2021; 39(1):18–25. https://doi.org/10.1016/j.vaccine.2020.11.032 PMID: 33246364.

3. Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD. Cochrane review of immunization policy development in Thailand: support for policies to vaccinate elderly people against influenza. Vaccine. 2013; 31 (50):6030–3. https://doi.org/10.1016/j.vaccine.2013.09.063 PMID: 24095882.

2. Surichan S, Wirachwong P, Supachaturachart C, Vamvoravudh P, et al. Development of influenza vaccine production capacity by the Government Pharmaceutical Organization of Thailand: addressing the threat of an influenza pandemic. Vaccine. 2011; 29:A29–A33. https://doi.org/10.1016/j.vaccine.2011.04.120 PMID: 21684425.

1. Schanzer DL, Langley JM, Tam TW. Co-morbidities associated with influenza-attributed mortality, 1994–2000, Canada. Vaccine. 2008; 26(36):4697–703. https://doi.org/10.1016/j.vaccine.2008.06.087 PMID: 18620016.
26. Wood JM, Major D, Heath A, Newman RW, Höschler K, Stephenson I, et al. Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard. Vaccine. 2012; 30(2):210–7. https://doi.org/10.1016/j.vaccine.2011.11.019 PMID: 22100887.

27. Suntronwong N, Vichiwattanapicha P, Klinfueng S, Korkong S, Thongmee T, Vongpunsawad S, et al. Climate factors influence seasonal influenza activity in Bangkok, Thailand. PloS one. 2020; 15(9): e0239729. https://doi.org/10.1371/journal.pone.0239729 PMID: 30911630.

28. Henry C, Palm A-KE, Krammer F, Wilson PC. From original antigenic sin to the universal influenza virus vaccine. Trends Immunol. 2018; 39(1):70–9. https://doi.org/10.1016/j.it.2017.08.003 PMID: 28867526.

29. Prachayangprecha S, Vichiwattanapicha P, Korkong S, Felber JA, Poovorawan Y. Influenza activity in Thailand and occurrence in different climates. SpringerPlus. 2015; 4(1):1–7. https://doi.org/10.1186/s40064-015-1149-6 PMID: 26191483.

30. Nuñez IA, Carlock MA, Allen JD, Owino SO, Moehling KK, Nowalk P, et al. Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains. PLoS One. 2017; 12(11):e0185666. https://doi.org/10.1371/journal.pone.0185666 PMID: 29091724.

31. Tewawong N, Suntronwong N, Vichiwattanapicha P, Vongpunsawad S, Theamboonlers A, Poovorawan Y. Genetic and antigenic characterization of hemagglutinin of influenza A/H3N2 virus from the 2015 season in Thailand. Virus Genes. 2016; 52(5):711–5. https://doi.org/10.1007/s11262-016-1347-5 PMID: 27146171.

32. Tewawong N, Suntronwong N, Korkong S, Theamboonlers A, Vongpunsawad S, Poovorawan Y. Evidence for influenza B virus lineage shifts and reassortants circulating in Thailand in 2014–2016. Infect Genet Evol. 2017; 47:35–40. https://doi.org/10.1016/j.meegid.2016.11.010 PMID: 27845268.

33. Nobusawa E, Sato K. Comparison of the mutation rates of human influenza A and B viruses. J Virol. 2006; 80(7):3675–8. https://doi.org/10.1128/JVI.80.7.3675-3678.2006 PMID: 16537638.

34. Muñoz IS, Rello SR, Lejarazu RO. Prevalence of antibodies and humoral response after seasonal trivalent vaccination against influenza B lineages in an elderly population of Spain. Enferm Infecc Microbiol Clin (Engl Ed). 2018; 36(9):572–575. English, Spanish. https://doi.org/10.1016/j.eimc.2017.10.021 PMID: 29179984.

35. Severson JJ, Richards KR, Moran JJ, Hayney MS. Persistence of influenza vaccine-induced antibody in lung transplant patients and healthy individuals beyond the season. Hum Vaccin Immunother. 2012; 8(12):1850–3. https://doi.org/10.4161/hv.21735 PMID: 22906937.

36. Dunning AJ, DiazGranados CA, Voloshen T, Hu B, Landolfi VA, Talbot HK. Correlates of protection against influenza in the elderly: results from an influenza vaccine efficacy trial. Clin Vaccine Immunol. 2016; 23(3):228–35. https://doi.org/10.1128/CVI.00604-15 PMID: 26762363.

37. Carlock MA, Ingram JG, Clutter EF, Cecil NC, Ramgopal M, Zimmerman RK, et al. Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses. Hum Vaccin Immunother. 2019; 15(9):2030–43. https://doi.org/10.1080/21645515.2019.1642056 PMID: 31291153.

38. Young B, Zhao X, Cook AR, Parry CM, Wilder-Smith A, I-Cheng MC. Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. Vaccine. 2017; 35(2):212–221. https://doi.org/10.1016/j.vaccine.2016.11.013 PMID: 27939013.

39. Grohskopf LA, Sokolow LZ, Olsen SJ, Breese JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 influenza season. MMWR Morb Mortal Wkly Rep. 2015; 64(30):818. https://doi.org/10.15585/mmwr.mm6430a3 PMID: 26247435.

40. Mantel C, Chu SY, Hyde TB, Lambach P, Group IPI. Seasonal influenza vaccination in middle-income countries: Assessment of immunization practices in Belarus, Morocco, and Thailand. Vaccine. 2020; 38 (2):212–8. https://doi.org/10.1016/j.vaccine.2019.10.028 PMID: 31699507.

41. Owusu JT, Prapasiri P, Ditsungnoen D, Leetongin G, Yoocharoen P, Rattanayot J, et al. Seasonal influenza vaccine coverage among high-risk populations in Thailand, 2010–2012. Vaccine. 2015; 33 (5):742–7. https://doi.org/10.1016/j.vaccine.2014.10.029 PMID: 25454855.

42. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerg Infect Dis. 2006; 12(1):48. https://doi.org/10.3201/eid1201.051237 PMID: 16494717.